Anti-CD79B antibodies and immunoconjugates and methods of use
US8722857B2 · kind B2 · utility
21Cited by
10References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2009 |
| Grant date | May 13, 2014 |
| Priority date | — |
| Expiry date | Oct 23, 2030 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.